For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Continued Tenofovir/Emtricitabine/Efavirenz | Tenofovir/emtricitabine/efavirenz : Continued therapy with tenofovir/emtricitabine/efavirenz | None | None | 0 | 15 | 3 | 15 | View |
| Switch to Tenofovir/Emtricitabine/Raltegravir | Tenofovir/emtricitabine/efavirenz is switched to tenofovir/emtricitabine/raltegravir Tenofovir/emtricitabine/raltegravir : Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine | None | None | 0 | 15 | 1 | 15 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Virologic failure | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Neutropenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Impaired fasting glucose | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| Diastolic hypertension | SYSTEMATIC_ASSESSMENT | Vascular disorders | None | View |